A study in patients with Catheter associated Blood Stream Infections, to study the drug resistance(capacity of disease causing micro-organisms to withstand exposure to drugs) and drug sensitivity patterns.
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: A419- Sepsis, unspecified organism
- Registration Number
- CTRI/2019/12/022454
- Lead Sponsor
- Department of Microbiology Kempegowda Institute of Medical Sciences Bangalore
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Subjects with Central Venous Catheters (CVCs) in situ for >3 days of insertion and sterile blood culture immediately after catheterization.
2.Subjects whose CVP tip samples when processed showed significant growth of one or more organisms.
Exclusion Criteria
1.Subjects who got central venous catheter (CVC) inserted outside our hospital.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To study the organisms causing CVC-BSI <br/ ><br>Timepoint: 6 months
- Secondary Outcome Measures
Name Time Method 1.To assess the antimicrobial susceptibility pattern among CVC-BSI isolates <br/ ><br>2.To study the clinical course and outcome of patients with CVC-BSI <br/ ><br>Timepoint: 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive antimicrobial resistance in CVC-BSI pathogens identified in CTRI/2019/12/022454?
How do emerging drug resistance patterns in CVC-BSI compare with standard-of-care antibiotic regimens?
What biomarkers correlate with clinical outcomes in CVC-BSI patients with sepsis (A419) as studied in CTRI/2019/12/022454?
What adverse events are associated with current antimicrobial therapies for CVC-BSI and how are they managed?
Are there novel combination therapies or alternative antimicrobial agents showing promise for CVC-BSI treatment?